Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial - Shaw, AT; Felip, E; Bauer, TM (Lancet Oncol, 2017)
et al.